This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Hyperbilirubinemia is a condition in which there is an excess of bilirubin in the bloodstream. Bilirubin is a yellowish compound produced by the breakdown of red blood cells, and the most common cause of hyperbilirubinemia is an increase in red blood cell breakdown. This can be caused by a variety of different conditions, including hemolytic anemia (a condition in which the body produces too many red blood cells), liver disease, certain medications, and some metabolic disorders. When bilirubin levels become too high, it can cause a variety of signs and symptoms such as jaundice (a yellow discoloration of the skin and eyes), itching, dark urine, and fatigue. Hyperbilirubinemia can also lead to serious complications such as kernicterus, a type of brain damage caused by prolonged exposure to high levels of bilirubin. The diagnosis of hyperbilirubinemia is typically made through a physical examination and laboratory tests that measure the levels of bilirubin in the blood. Treatment depends on the underlying cause of the condition, but may include medications, such as phototherapy or exchange transfusions, to reduce the bilirubin levels. In some cases, treatment may also involve lifestyle adjustments such as avoiding certain medications or foods that can increase bilirubin levels. Hyperbilirubinemia is a potentially serious condition, but with prompt diagnosis and treatment, most people experience an improvement in their symptoms and an overall improvement in their health. It is important to speak with a healthcare provider if you are experiencing any symptoms of hyperbilirubinemia.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States